“Changes in the concentration of EGFR-mutated plasma DNA in the first hours of anti-EGFR therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer”, Вопр. онкол., vol. 67, no. 5, pp. 665–674, Oct. 2021, doi: 10.37469/0507-3758-2021-67-5-665-674.